ISSN 1671-5411 CN 11-5329/R
Volume 18 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Please cite this article as: XING FW, ZHANG LH, ZHANG HB, BAI XK, HU DL, ZHENG X, LI J. Beta-blockers and 1-year clinical outcomes in hospitalized heart failure patients with atrial fibrillation. J Geriatr Cardiol 2021; 18(9): 728−738. DOI: 10.11909/j.issn.1671-5411.2021.09.010
Citation: Please cite this article as: XING FW, ZHANG LH, ZHANG HB, BAI XK, HU DL, ZHENG X, LI J. Beta-blockers and 1-year clinical outcomes in hospitalized heart failure patients with atrial fibrillation. J Geriatr Cardiol 2021; 18(9): 728−738. DOI: 10.11909/j.issn.1671-5411.2021.09.010

Beta-blockers and 1-year clinical outcomes in hospitalized heart failure patients with atrial fibrillation

doi: 10.11909/j.issn.1671-5411.2021.09.010
More Information
  •  OBJECTIVE  To assess the association between beta-blockers and 1-year clinical outcomes in heart failure (HF) patients with atrial fibrillation (AF), and further explore this association that differs by left ventricular ejection fraction (LVEF) level.  METHODS  We enrolled hospitalized HF patients with AF from China Patient-centered Evaluative Assessment of Cardiac Events Prospective Heart Failure Study. COX proportional hazard regression models were employed to calculate hazard ratio of beta-blockers. The primary outcome was all-cause death.  RESULTS  Among 1762 HF patients with AF (756 women [41.4%]), 1041 (56%) received beta-blockers at discharge and 1272 (72.2%) had an LVEF > 40%. During one year follow up, all-cause death occurred in 305 (17.3%), cardiovascular death occurred in 203 patients (11.5%), and rehospitalizations for HF occurred in 622 patients (35.2%). After adjusting for demographic characteristics, social economic status, smoking status, medical history, anthropometric characteristics, and medications used at discharge, the use of beta-blockers at discharge was not associated with all-cause death [hazard ratio (HR): 0.86; 95% Confidence Interval (CI): 0.65−1.12; P = 0.256], cardiovascular death (HR: 0.76, 95% CI: 0.52−1.11; P = 0.160), or the composite outcome of all-cause death and HF rehospitalization (HR: 0.97, 95% CI: 0.82−1.14; P = 0.687) in the entire cohort. There were no significant interactions between use of beta-blockers at discharge and LVEF with respect to all-cause death, cardiovascular death, or composite outcome. In the adjusted models, the use of beta-blockers at discharge was not associated with all-cause death, cardiovascular death, or composite outcome across the different levels of LVEF: reduced (< 40%), mid-range (40%−49%), or preserved LVEF (≥ 50%).  CONCLUSION  Among HF patients with AF, the use of beta-blockers at discharge was not associated with 1-year clinical outcomes, regardless of LVEF.
  • loading
  • [1]
    Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail 2020; 22: 1342−1356. doi: 10.1002/ejhf.1858
    [2]
    Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123−1133. doi: 10.1016/j.jacc.2013.11.053
    [3]
    Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47: 1997−2004. doi: 10.1016/j.jacc.2006.01.060
    [4]
    Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129−200. doi: 10.1093/eurheartj/ehw128
    [5]
    Kotecha D, Holmes J, Krum H, et al. Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235−2243. doi: 10.1016/S0140-6736(14)61373-8
    [6]
    Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39: 26−35. doi: 10.1093/eurheartj/ehx564
    [7]
    Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110−118. doi: 10.1093/eurjhf/hfs141
    [8]
    Silverman DN, Plante TB, Infeld M, et al. Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT Trial. JAMA Netw Open 2019; 2: e1916598. doi: 10.1001/jamanetworkopen.2019.16598
    [9]
    Lund LH, Benson L, Dahlström U, et al. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 2014; 312: 2008−2018. doi: 10.1001/jama.2014.15241
    [10]
    Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42: 373−498. doi: 10.1093/eurheartj/ehaa612
    [11]
    Huang X, Yu Y, Li X, et al. The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design. BMJ Open 2019; 9: e025144. doi: 10.1136/bmjopen-2018-025144
    [12]
    Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation 2018; 137: 961−972. doi: 10.1161/CIRCULATIONAHA.117.033502
    [13]
    [Chinese guidelines for the diagnosis and treatment of heart failure 2018]. Zhonghua Xin Xue Guan Bing Za Zhi 2018; 46: 760-89. [Article in Chinese].
    [14]
    Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 2017; 69: 2885−2896. doi: 10.1016/j.jacc.2017.04.001
    [15]
    Khairy P, Roy D. Atrial fibrillation: challenging the status quo: β-blockers for HF plus AF. Nat Rev Cardiol 2014; 11: 690−692. doi: 10.1038/nrcardio.2014.166
    [16]
    Mareev Y, Cleland JG. Should beta-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther 2015; 37: 2215-2224.
    [17]
    Takada T, Sakata Y, Miyata S, et al. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 study. Eur J Heart Fail 2014; 16: 309−316.
    [18]
    Rienstra M, Van Gelder IC, Van den Berg MP, et al. A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. Int J Cardiol 2006; 109: 95−100. doi: 10.1016/j.ijcard.2005.05.054
    [19]
    Mulder BA, Van Veldhuisen DJ, Crijns HJ, et al. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail 2013; 15: 1311−1318. doi: 10.1093/eurjhf/hft093
    [20]
    Campodonico J, Piepoli M, Clemenza F, et al. Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation. Int J Cardiol 2018; 273: 141−146. doi: 10.1016/j.ijcard.2018.08.012
    [21]
    Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an af-chf substudy. JACC Heart Fail 2017; 5: 99−106. doi: 10.1016/j.jchf.2016.10.015
  • JGC-202103-008-R1Supplementary.pdf
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Article Metrics

    Article views (50) PDF downloads(13) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return